Medincell
Medincell SA is a French biopharmaceutical company developing long-acting injectable prescription drugs utilizing its proprietary BEPO technology platform. The company formulates polymer-based injectable therapies for CNS disorders, pain management, and oncology, including Uzedy for schizophrenia commercialized with Teva. Revenue is primarily generated through research collaboration upfront payments, clinical development milestone fees, and commercial sales royalties from pharmaceutical partners. Core end markets encompass psychiatry clinics, hospital neurology departments, pain treatment centers, and prescription patients in North America and Europe. Medincell holds an innovative pioneer position in the global biopharmaceutical sector for long-acting injectable drug delivery platforms. The company is headquartered in Jacou, France, and its ordinary shares trade on Euronext Paris.
2 of the funds FundTelligence covers report a position in Medincell.
- Legal name
- MEDINCELL SA
- Sector
- Health Care
- Country
- France
- Funds holding it
- 2
Funds holding Medincell
- Lannebo Europa Småbolag — Lannebo · 1.85 % (full portfolio disclosed, June 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.11 % (full portfolio disclosed, October 2026)